Premium
Circulating microRNAs as potential biomarkers for genetic generalized epilepsies: a three microRNA panel
Author(s) -
MartinsFerreira R.,
Chaves J.,
Carvalho C.,
Bettencourt A.,
Chorão R.,
Freitas J.,
Samões R.,
Boleixa D.,
Lopes J.,
Ramalheira J.,
Silva B. M.,
Martins da Silva A.,
Costa P. P.,
Leal B.
Publication year - 2020
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/ene.14129
Subject(s) - microrna , biomarker , medicine , diagnostic biomarker , receiver operating characteristic , oncology , epileptogenesis , real time polymerase chain reaction , area under the curve , bioinformatics , gene , genetics , biology , hippocampal formation
Background and purpose Genetic generalized epilepsies (GGEs) encompass a group of syndromes of mainly genetic causes, characterized by the involvement of both hemispheres. MicroRNAs (miRNAs) are small non‐coding RNAs with a critical role in the regulation of neuronal biological processes through gene expression modulation. Dysregulated miRNA expression has been shown in epilepsy. Due to their stability in biological fluids like serum, miRNAs have assumed a prominent role in biomarker research. Our aim was to evaluate circulating levels of three miRNAs in GGE patients and assess their putative diagnostic value. Methods MiR‐146a, miR‐155 and miR‐132 were quantified by real‐time polymerase chain reaction in the serum of 79 GGE patients (47 women, 32 men, 35.1 ± 12.4 years) and 67 healthy individuals (41 women, 26 men, 42.4 ± 10.1 years). Relative expression values were calculated using the 2 –ΔΔCt method. Receiver operating characteristic curve analysis was performed to assess diagnostic value. MiRNA expression was correlated with clinicopathological features. Results Serum levels of miR‐146a and miR‐155 were significantly upregulated in GGE patients relative to controls (3.13 and 6.05, respectively). Combined miR‐146a, miR‐155 and miR‐132 serum levels performed well as a diagnostic biomarker, discriminating GGE patients from controls with an area under the curve of 0.85, 80% specificity and 73% sensitivity. Conclusions Our results indicate that miR‐146a, miR‐155 and miR‐132 may partake in GGE epileptogenesis. A panel of three circulating miRNAs with potential value as a GGE biomarker is reported for the first time. Novel biomarkers may help to identify new treatment targets and contribute to improved patients’ quality of life through earlier diagnosis and a more precise prognosis.